Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. Schinke C, et al. Among authors: walker b. Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. Haematologica. 2017. PMID: 28522572 Free PMC article. No abstract available.
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. Jenner MW, et al. Blood. 2007 Nov 1;110(9):3291-300. doi: 10.1182/blood-2007-02-075069. Epub 2007 Jul 3. Blood. 2007. PMID: 17609426 Free article.
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ. Leone PE, et al. Clin Cancer Res. 2008 Oct 1;14(19):6033-41. doi: 10.1158/1078-0432.CCR-08-0347. Clin Cancer Res. 2008. PMID: 18829482 Free PMC article.
Aminopeptidase inhibition as a targeted treatment strategy in myeloma.
Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Moore HE, et al. Mol Cancer Ther. 2009 Apr;8(4):762-70. doi: 10.1158/1535-7163.MCT-08-0735. Mol Cancer Ther. 2009. PMID: 19372548 Free article.
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ. Dickens NJ, et al. Clin Cancer Res. 2010 Mar 15;16(6):1856-64. doi: 10.1158/1078-0432.CCR-09-2831. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215539 Free PMC article. Clinical Trial.
3,571 results